3M introduces new 3M Ioban 2 antimicrobial incise drape 6661EZ to provide a simplified, one‐person application
3M announced at the American College of Surgeons Clinical Congress the national introduction of the 3M Ioban 2 antimicrobial incise drape, a unique antimicrobial surgical drape designed with a ‘picture frame’ delivery system. The 10.5‐in. × 8‐in. drape is ideally suited for high‐volume minimally invasive implant procedures. The new Ioban 2 drape is made with a strong, conformable and breathable polyester incise film coated with medical grade acrylate adhesive containing molecular iodine (I2) as the active antimicrobial agent. The Ioban 2 drape provides a sterile surface and helps to decrease bacterial contamination from skin to gloves, gowns, instruments and implants.
A drape’s barrier and antimicrobial properties are fully effective only when the drape is securely adhered to the patient’s skin. Clinical studies show that Ioban 2 incise drapes adhere better to skin than other drapes, especially after several hours. The Ioban 2 drape is identical in clinical performance and efficacy to 3M’s other Ioban 2 antimicrobial incise drapes and offers the advantage of quick, easy and precise drape placement every time. Additionally, the drape is made with a superior‐quality adhesive.
The Ioban 2 drape helps prevent surgical site infections by reducing bacterial migration from the patient’s skin to the surgical wound. The skin is a significant source of potentially infectious microorganisms, such as Staphylococci aureus and coagulase‐negative staphylococci, which are becoming increasingly resistant to antibiotics and account for more than a third of all surgical wound infections.
In addition, surgical site infections contribute to or directly cause more than 10 000 deaths each year in the United States of America. The Ioban 2 drape provides documented continuous antimicrobial activity and is clinically proven to reduce the risks of wound contamination and bacterial migration. The broad‐spectrum antimicrobial activity lasts for hours under the drape where it cannot be washed away.
For more information about the Ioban 2 drape, visit http://www.3M.com/infectionprevention.
Dermagenics announces United Kingdom (UK) launch of new wound care technology: Epi‐Max EU™ debuted at the wounds UK harrogate international conference
Greystone Pharmaceuticals Inc., through its European subsidiary Dermagenics Europe, today announced the UK launch of its chronic wound technology, Epi‐Max EU.
Epi‐Max EU is indicated for use as a wound dressing to manage diabetic ulcers, decubitus ulcers, leg ulcers and acute severe wounds where fast epithelialisation is required. It is the first wound care product allowed to claim the ability to downregulate matrix metalloproteases (MMP) production. Studies have shown this downregulation enhances the healing of chronic and acute severe wounds. The product is currently marketed and sold under the DerMax® name throughout Europe and the Middle East. The success of DerMax in progressing chronic wounds towards healing was featured in a peer‐reviewed article recently published in ‘Advances in Skin & Wound Care’ (July/August 2006 Vol. 19 No. 6).
‘We are encouraged by the success of DerMax throughout the continent and look forward to bringing this state‐of‐the‐art technology to the United Kingdom’, stated Greg Pilant, Chairman and chief executive officer of Greystone Pharmaceuticals Inc. ‘Our mission is to provide the health care community with wound care alternatives that are effective in accelerating the healing process’.
Epi‐Max EU made its UK debut at the Wounds UK International Conference held in Harrogate 13–15 November 2006. The product, which has been approved for the Drug Tariff list, is expected to be available for distribution on 1 January 2007.
More information about Greystone and its products can be found at http://www.greystonepharmaceuticals.com; http://www.epimax.eu; and http://www.dermax.com.